News

◄ Back

February 5, 2007, Germantown WI, USA -- Cambridge Major Laboratories, Inc today announced it has partnered with Arlington Capital Partners to build a full service drug development organization focused in three primary areas: 1) Active Pharmaceutical Ingredient (API), 2) Formulation, and 3) Regulatory Consulting Services. Cambridge Major, an outsourced chemistry services provider to the world’s leading pharmaceutical and biotechnology firms, will serve as the platform company to assemble a portfolio of critical services for pharmaceutical customers seeking to accelerate and maximize their drug development process.

Cambridge Major has demonstrated exceptional growth over the past five years averaging revenue growth of over 30% per year. Arlington Capital brings significant relationships, strategic focus and significant capital to fuel further expansion of Cambridge Major, and to help fund acquisition activities in complimentary businesses areas including formulation, regulatory consulting, clinical packaging/distribution and physical form determination. Cambridge Major’s goal is to pursue mid-sized companies with healthy business fundamentals from each of these key segments of the development services arena. Leveraging each piece as entrepreneurial and well-functioning units will enable the overall organization to operate even more effectively and expeditiously.

Cambridge Major will continue to be led by its Chief Executive Officer, Michael Major, Ph.D., D.Sc., in conjunction with Cambridge Major’s management team, who have been responsible for the company’s growth since its founding seven years ago.

“With access to Arlington Capital’s financial and strategic resources Cambridge Major will establish, in a short period of time, a fully integrated API delivery system consisting of three main functions including synthesis of API’s, formulation, and CMC consulting, augmented by physical characterization, clinical packaging and distribution.”, said Michael Major, Ph.D., D.Sc., President and CEO Cambridge Major Laboratories. “By offering all of the services needed to provide materials for initial toxicity and clinical studies the new conglomerate will significantly shorten the time needed to start these pivotal studies. With this “one stop shop” model and our unmatched capabilities, clients won’t have to worry about tech transfers, coordinating material shipments, packaging, distribution, and FDA filing documentation. At the end of the day we will provide clients with what they need - compiled results and final reports all done through integrated functions. This translates to better execution, faster delivery and big savings. Having an integrated functional system will enable us to share many of our resources, expand our markets and provide more comprehensive services to our customers.”

Peter Manos of Arlington Capital stated, “We are very pleased to establish our partnership with Cambridge Major. Michael Major and his team have established a world class organization in the chemistry services industry and we look forward to facilitating the Company’s expansion as it builds on its significant success to date.”

About Cambridge Major Labs:
Cambridge Major Laboratories, Inc. is a service-based chemistry outsourcing partner to the world’s leading pharmaceutical and biotechnology companies, producing pharmaceutical intermediates, API’s, and other fine organic chemicals. Specializing in chemical process development and advanced multi-step organic synthesis, the Company operates two facilities near Milwaukee, Wisconsin including process chemistry laboratories, kilo labs, a pilot plant, and complete analytical laboratories. The Company has been FDA inspected and approved for cGMP manufacturing. Visit us at www.c-mlabs.com.

Contact:
Michael Major, President/CEO or Brian Scanlan, VP Corporate Development
Cambridge Major Laboratories
W130 N10497 Washington Drive
Germantown, WI 53022
phone: 262-251-5044
fax: 262-438-0282
email: m.major@c-mlabs.com or b.scanlan@c-mlabs.com


About Arlington Capital Partners:
Arlington Capital Partners (www.arlingtoncap.com) is a Washington, DC-based private equity fund with over $1 billion of committed capital focused on middle market buyout investment opportunities in growth industries including: healthcare services, aerospace/defense, business services and outsourcing, media and education. The firm’s professionals have a unique combination of operating and private equity experience that enables Arlington to be a value-added investor. Arlington invests in companies in partnership with high quality management teams that are motivated to establish and/or advance their company’s position as leading competitors in their field.

Contact:
Peter Manos or Matthew Altman
Arlington Capital Partners
600 New Hampshire Ave., NW
Suite 660
Washington, DC 20037
(202) 337-7500
(202) 337-7525 (fax)

◄ Back